Citadel Advisors
EIGR

Citadel Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Citadel Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-334
Closed -$2.25K – 15713
2023
Q4 		$2.25K Buy
+334
New +$2.94K ﹤0.01% 13720
2023
Q1 		– Sell
-4,023
Closed -$187K – 15785
2022
Q4 		$142K Buy
4,023
+1,387
+53% +$167K ﹤0.01% 10688
2022
Q3 		$595K Buy
+2,636
New +$648K ﹤0.01% 8083
2022
Q1 		– Sell
-3,970
Closed -$627K – 14857
2021
Q4 		$618K Buy
3,970
+1,951
+97% +$377K ﹤0.01% 9154
2021
Q3 		$405K Buy
+2,019
New +$480K ﹤0.01% 10383
2021
Q2 		– Sell
-29,665
Closed -$7.4M – 14641
2021
Q1 		$7.88M Sell
29,665
-1,978
-6% -$623K ﹤0.01% 3359
2020
Q4 		$11.7M Buy
31,643
+2,066
+7% +$593K ﹤0.01% 2438
2020
Q3 		$7.22M Buy
29,577
+134
+0.5% +$41.7K ﹤0.01% 2659
2020
Q2 		$8.48M Buy
29,443
+1,000
+4% +$295K ﹤0.01% 2418
2020
Q1 		$5.8M Buy
28,443
+13,931
+96% +$4.44M ﹤0.01% 2521
2019
Q4 		$6.49M Buy
14,512
+181
+1% +$64.2K ﹤0.01% 2748
2019
Q3 		$4.41M Buy
14,331
+4,370
+44% +$1.42M ﹤0.01% 3284
2019
Q2 		$3.17M Buy
+9,961
New +$3.45M ﹤0.01% 3771
2016
Q1 		– Sell
-168
Closed -$111K – 8224
2015
Q4 		$111K Buy
168
+98
+140% +$55.4K ﹤0.01% 6568
2015
Q3 		$33K Sell
70
-140
-67% -$74.3K ﹤0.01% 7858
2015
Q2 		$119K Buy
210
+193
+1,135% +$534K ﹤0.01% 6911
2015
Q1 		$141K Buy
+17
New +$149K ﹤0.01% 6553

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Citadel Advisors's EIGR Position: Q1 2024 in Review

Citadel Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 334 shares — an estimated $2.25K sold.

Citadel Advisors first reported a position in EIGR in Q1 2015 and held it in 17 quarters. The position peaked at $11.7M in Q4 2020. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Citadel Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 334 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $2.25K.
  • Citadel Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 17 quarters.
  • Citadel Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $11.7M in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.